Nemolizumab (CIM331) is a humanized monoclonal antibody against human interleukin-31 receptor A that inhibits the binding and subsequent signal transduction of interleukin-31 (IL-31) to its receptor. Nemolizumab can be used to study atopic dermatitis with pruritus.